A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

被引:62
作者
Adiwijaya, Bambang S. [1 ]
Herrmann, Eva [2 ]
Hare, Brian [1 ]
Kieffer, Tara [1 ]
Lin, Chao [1 ]
Kwong, Ann D. [1 ]
Garg, Varun [1 ]
Randle, John C. R. [1 ]
Sarrazin, Christoph [3 ]
Zeuzem, Stefan [3 ]
Caron, Paul R. [1 ]
机构
[1] Vertex Pharmaceut Inc, Cambridge, MA USA
[2] Goethe Univ Frankfurt, Inst Biostat & Math Modeling, Fac Med, Frankfurt, Germany
[3] JW Goethe Univ Hosp, Med Klin 1, Frankfurt, Germany
关键词
HEPATITIS-C VIRUS; HIV-1; DRUG-RESISTANCE; PEGINTERFERON ALPHA-2A; TELAPREVIR VX-950; INTERFERON-ALPHA; SERINE-PROTEASE; RAPID DECLINE; MUTATION-RATE; WILD-TYPE; THERAPY;
D O I
10.1371/journal.pcbi.1000745
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was estimated using a model in which variants were selected by competition for shared limited replication space. Fitness was represented in the absence of telaprevir by different variant production rate constants and in the presence of telaprevir by additional antiviral blockage by telaprevir. Model parameters, including rate constants for viral production, clearance, and effective telaprevir concentration, were estimated from 1) plasma HCV RNA levels of subjects before, during, and after dosing, 2) post-dosing prevalence of plasma variants from subjects, and 3) sensitivity of variants to telaprevir in the HCV replicon. The model provided a good fit to plasma HCV RNA levels observed both during and after telaprevir dosing, as well as to variant prevalence observed after telaprevir dosing. After an initial sharp decline in HCV RNA levels during dosing with telaprevir, HCV RNA levels increased in some subjects. The model predicted this increase to be caused by pre-existing variants with sufficient fitness to expand once available replication space increased due to rapid clearance of wild-type (WT) virus. The average replicative fitness estimates in the absence of telaprevir ranged from 1% to 68% of WT fitness. Compared to the relative fitness method, the in vivo estimates from the viral dynamic model corresponded more closely to in vitro replicon data, as well as to qualitative behaviors observed in both on-dosing and long-term post-dosing clinical data. The modeling fitness estimates were robust in sensitivity analyses in which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied.
引用
收藏
页数:13
相关论文
共 49 条
[1]  
Adiwijaya BS, 2009, ANTIVIR THER, V14, P591
[2]   Biological network design strategies: discovery through dynamic optimization [J].
Adiwijaya, Barnbang S. ;
Barton, Paul I. ;
Tidor, Bruce .
MOLECULAR BIOSYSTEMS, 2006, 2 (12) :650-659
[3]   Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects [J].
Bartels, Doug J. ;
Zhou, Yi ;
Zhang, Eileen Z. ;
Marcial, Michelle ;
Byrn, Randal A. ;
Pfeiffer, Thomas ;
Tigges, Ann M. ;
Adiwijaya, Bambang S. ;
Lin, Chao ;
Kwong, Ann D. ;
Kieffer, Tara L. .
JOURNAL OF INFECTIOUS DISEASES, 2008, 198 (06) :800-807
[4]   Absence of HCV viral recombination following superinfection [J].
Bernardin, F. ;
Herring, B. ;
Page-Shafer, K. ;
Kuiken, C. ;
Delwart, E. .
JOURNAL OF VIRAL HEPATITIS, 2006, 13 (08) :532-537
[5]   Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine [J].
Conway, B ;
Wainberg, MA ;
Hall, D ;
Harris, M ;
Reiss, P ;
Cooper, D ;
Vella, S ;
Curry, R ;
Robinson, P ;
Lange, JMA ;
Montaner, JSG .
AIDS, 2001, 15 (10) :1269-1274
[6]  
Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[7]   Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations [J].
Devereux, HL ;
Emery, VC ;
Johnson, MA ;
Loveday, C .
JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (02) :218-224
[8]   HIV dynamics with multiple infections of target cells [J].
Dixit, NM ;
Perelson, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (23) :8198-8203
[9]   Modelling how ribavirin improves interferon response rates in hepatitis C virus infection [J].
Dixit, NM ;
Layden-Almer, JE ;
Layden, TJ ;
Perelson, AS .
NATURE, 2004, 432 (7019) :922-924
[10]  
*FDA, 2002, PEG BRIEF DOC